Understanding specific GC subtypes is crucial due to molecular diversity, as data suggests that patients with Epstein-Barr virus-associated (EBV+) and microsatellite instability-high (MSI-H) tumours, which are linked to higher PD-L1 expression, may respond to anti-PD-1/PD-L1 therapy (22,23) This potential responsiveness may be linked to the high mutational burden and neo-antigen generation associated with MSI-high tumours (24). The gene discussed is CD274; the disease is neoplasm.